GSK: ViiV starts phase III study in HIV prevention.
(CercleFinance.com) - ViiV Healthcare, which is majority-owned by GSK, is starting a phase III study on experimental drug cabotegravir for HIV prevention in sexually active women.
The study will assess injections of cabotegravir given every two months compared with daily oral pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate.
The study aims to enrol 3,200 women aged 18 to 45 years old from sub-Saharan African countries.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The study will assess injections of cabotegravir given every two months compared with daily oral pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate.
The study aims to enrol 3,200 women aged 18 to 45 years old from sub-Saharan African countries.
Copyright (c) 2017 CercleFinance.com. All rights reserved.